COTI Reports Positive Data From In-animal Model Of Human Pancreatic Cancer

Critical Outcome Technologies (COTI) has announced positive results from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the already impressive data package for COTI-2, demonstrating efficacy as a single agent and in combination with first line therapies with low toxicity in seven different animal models of human cancers.

The study was designed to determine first, the effectiveness of oral COTI-2 as a single agent, second, the effectiveness of COTI-2 in combination with Gemcitabine, and third, the toxicity of chronically administered oral COTI-2 as a single agent and in combination with Gemcitabine in an animal xenograft model of human pancreatic cancer (PANC-1).

In the study, COTI-2 as a single agent demonstrated efficacy comparable to Gemcitabine. COTI-2 plus Gemcitabine was significantly more effective than Gemcitabine as a single agent. This result was observed early and increased throughout the duration of the study.

Partial tumor regressions were observed in the combination treatment group. Chronic oral treatment with COTI-2 as a single agent or in combination with Gemcitabine was well tolerated with no treatment deaths or observable toxicity over the duration of the study.

Wayne Danter, president and CSO of COTI, said: “The results of these experiments indicate that chronically administered oral COTI-2 is a well tolerated single agent with efficacy comparable to the first-line agent Gemcitabine, and there is enhanced efficacy in combination with Gemcitabine in an animal model of human pancreatic cancer.

These results are significant because they add to the impressive data set of COTI-2, showing effectiveness, particularly in combination with first and second line agents, against multiple cancers and low toxicity.”

Michael Cloutier, CEO of COTI, said: “We are delighted with these new scientific results providing evidence supporting the commercial potential of oral COTI-2 in pancreatic cancer. COTI looks forward to sharing this new data with parties who have expressed interest in a commercial partnership related to COTI-2.”